Comphya has raised CHF7.5M in a Series A funding round led by CEO Pim van Wesel to advance their neurostimulation therapy for erectile dysfunction.

Jul 08, 2025•8 days ago

Amount Raised

CHF7.5 Million

Round Type

series a

LausanneBiotechnologyHealth Care

Description

Comphya SA, a Lausanne-based MedTech company, closed a Series A financing round totaling CHF 7.5M. The funding will support their development of CaverSTIM™, a device for patients with erectile dysfunction unresponsive to medication. Recent clinical results have encouraged the company's growth trajectory. Comphya plans to secure additional funds through a Series B round in 2026.

Company Information

Company

Comphya

Location

Lausanne, Vaud, Switzerland

About

Comphya is a Swiss medical device company, spin-off from the Swiss Federal Institute of Technology (EPFL). Its mission is to overcome the major clinical problems of erectile dysfunction (ED) in spinal cord injury and post-prostatectomy patients (non-responders to oral drugs). Our innovation lies on neuroprosthetics principles and will offer a unique and superior treatment for ED. Our goal is to fulfill patient needs through safe and effective medical devices, offering life quality in large parts of the male population in great need.

Comphya has raised CHF7.5M in a Series A funding round led by CEO Pim van Wesel to advance their neurostimulation therapy for erectile dysfunction.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information